Verition Fund Management LLC Makes New $738,000 Investment in AnaptysBio, Inc. (NASDAQ:ANAB)

Verition Fund Management LLC purchased a new stake in AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 22,036 shares of the biotechnology company's stock, valued at approximately $738,000. Verition Fund Management LLC owned approximately 0.07% of AnaptysBio as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in ANAB. Frazier Life Sciences Management L.P. boosted its position in shares of AnaptysBio by 140.7% during the second quarter. Frazier Life Sciences Management L.P. now owns 2,165,591 shares of the biotechnology company's stock valued at $54,270,000 after purchasing an additional 1,265,891 shares in the last quarter. FMR LLC boosted its holdings in shares of AnaptysBio by 15.3% during the 3rd quarter. FMR LLC now owns 3,309,175 shares of the biotechnology company's stock valued at $110,857,000 after buying an additional 438,557 shares in the last quarter. Jennison Associates LLC purchased a new stake in shares of AnaptysBio in the 3rd quarter worth about $8,874,000. Victory Capital Management Inc. increased its stake in shares of AnaptysBio by 677.9% in the 3rd quarter. Victory Capital Management Inc. now owns 237,250 shares of the biotechnology company's stock worth $7,948,000 after acquiring an additional 206,750 shares in the last quarter. Finally, Assenagon Asset Management S.A. lifted its position in AnaptysBio by 55.1% during the 3rd quarter. Assenagon Asset Management S.A. now owns 475,446 shares of the biotechnology company's stock valued at $15,927,000 after acquiring an additional 168,813 shares during the period.

AnaptysBio Price Performance

Shares of ANAB traded up $0.21 during trading hours on Tuesday, hitting $23.09. The stock had a trading volume of 364,978 shares, compared to its average volume of 362,274. AnaptysBio, Inc. has a 12 month low of $15.84 and a 12 month high of $41.31. The stock has a fifty day moving average price of $26.72 and a 200 day moving average price of $29.68. The firm has a market capitalization of $702.63 million, a PE ratio of -3.80 and a beta of -0.11.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last issued its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported ($1.14) earnings per share for the quarter, topping the consensus estimate of ($1.72) by $0.58. AnaptysBio had a negative net margin of 289.75% and a negative return on equity of 287.94%. The firm had revenue of $30.02 million for the quarter, compared to analysts' expectations of $7.92 million. As a group, analysts anticipate that AnaptysBio, Inc. will post -6.02 EPS for the current fiscal year.

Insider Transactions at AnaptysBio

In other AnaptysBio news, CFO Dennis Mulroy sold 12,220 shares of the company's stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $39.91, for a total value of $487,700.20. Following the completion of the transaction, the chief financial officer now directly owns 4,744 shares in the company, valued at $189,333.04. This represents a 72.03 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Eric J. Loumeau sold 8,720 shares of AnaptysBio stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $39.82, for a total transaction of $347,230.40. Following the sale, the insider now owns 7,020 shares in the company, valued at approximately $279,536.40. The trade was a 55.40 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 22,440 shares of company stock worth $892,936 in the last three months. Corporate insiders own 33.70% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts have weighed in on ANAB shares. Wedbush reaffirmed an "outperform" rating and set a $42.00 target price on shares of AnaptysBio in a research note on Thursday, November 14th. UBS Group upped their price target on AnaptysBio from $23.00 to $33.00 and gave the stock a "neutral" rating in a research note on Wednesday, October 30th. Guggenheim lifted their price objective on AnaptysBio from $75.00 to $90.00 and gave the company a "buy" rating in a research note on Monday, October 21st. HC Wainwright cut their target price on AnaptysBio from $55.00 to $52.00 and set a "buy" rating on the stock in a research note on Wednesday, November 6th. Finally, BTIG Research lowered AnaptysBio from a "buy" rating to a "neutral" rating in a research report on Monday, December 2nd. Three analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $54.64.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.